GENERAL CONSIDERATIONS


General Considerations

•renal cystadenocarcinoma is an autosomal dominant condition in GSD with a genetic linkage to chromosome 5

•renal cystadenocarcinoma represent 6% of all renal tumors in GSD

•renal cystadenocarcinoma has also been described in a GSD-cross dog and Golden Retriever

•renal cystadenocarcinoma is a bilateral disease with slowly progressive deterioration of renal function

•renal cystadenocarcinoma is associated with nodular dermatofibrosis and uterine leiomyoma

•nodular dermatofibrosis is present in all cases and appear as small, firm, and mobile subcutaneous masses


Biologic Behaviour

•clinical signs are worse with bilateral disease and the size of skin and uterine tumors increase with advancing age

•metastasis reported in up to 47% of cases:

•metastatic sites including sternal and abdominal lymph nodes, liver, lungs, pleura, and peritoneum

•metastasis is more common with large, solid, and poorly differentiated tumors

•main causes of death are renal failure, metastatic disease and secondary skin infections



DIAGNOSIS


Clinical Signs

•clinical signs are non-specific such as abdominal enlargement and abdominal pain

•urinary signs are uncommon

•skin lesions (i.e., dermatofibrosis) are associated with renal cystadenocarcinomas in GSD

•lameness caused by either skeletal metastases or hypertrophic osteopathy


Urinalysis and Urine Sediment Cytology

•proteinuria is a common finding with renal tumors

•hematuria is uncommon

•urine sediment cytology is rarely diagnostic for renal tumors


Blood Tests

•hematology and serum biochemistry findings are usually normal or non-specific

•mild-to-moderate normochromic, normocytic anemia can be caused by either hematuria or bone marrow suppression secondary to chronic disease

•polycythemia is a reported paraneoplastic syndrome with renal tumors

•uremia may result from obstruction of urinary outflow, bilateral renal tumors, or age-related renal failure


Imaging


General Considerations

•survey abdominal and thoracic radiographs, contrast radiography, ultrasonography, CT, and MRI are imaging modalities used to identify the presence and extent of renal tumors


Survey Abdominal Radiography

•survey abdominal radiographic findings: sublumbar lymph node enlargement, renomegaly, and skeletal metastases, especially lumbar vertebrae and pelvis

•abdominal mass is identified in 81% and localized to the kidney in 54% of dogs with primary renal tumors

•focal mineralization can be observed but difficult to differentiate tumor from renal calculi and GI opacities


Excretory Urography

•excretory urographic findings: space occupying renal mass, variable opacification of the renal parenchyma, and distortion of the renal pelvis

•excretory urography successfully identifies a renal mass in 96% dogs with primary renal tumors


Ultrasonography

•ultrasonography results in earlier diagnosis and more successful treatment of renal neoplasia in humans

•renal tumors, except for LSA, produce a mixed echogenicity with disruption of the normal renal architecture

•renal LSA is usually hypoechoic

•ultrasonography is also useful in detecting neoplastic involvement of regional lymph nodes and adjacent structures such as the adrenal glands ± caudal vena cava


Advanced Imaging

•CT scans are used for the diagnosis and local staging of renal neoplasia with a high correlation between CT findings and gross pathology

•MRI is preferred for identifying adjacent vascular and visceral invasion, especially if renal-sparing surgery is planned

•other imaging techniques include caval venography and nuclear scintigraphy


Biopsy

•biopsy is required for definitive diagnosis of renal tumors

•biopsy techniques: FNA, needle biopsy, and wedge biopsy

•FNA and needle-core biopsy can be performed using a blind, ultrasound-guided, laparoscopic, or open technique

•ultrasound-guided biopsy is a rapid, safe, and accurate technique for diagnosing focal and diffuse renal disease

•blind percutaneous needle biopsy can be performed in cats where the kidney can be immobilized by palpation

•percutaneous biopsy should be performed with bilateral renal lesions or suspected renal LSA

•single procedure surgical biopsy, staging, and definitive treatment preferred for unilateral lesions

•complications of needle biopsy: minor localized hemorrhage, microscopic hematuria, and tumor seeding


Clinical Staging




























TREATMENT


Surgery

•surgical management depends on behaviour of the tumor, presence of metastases and bilateral renal involvement, and invasion of the caudal vena cava and adjacent structures

•nephroureterectomy is recommended for:

•malignant renal and ureteral tumors except LSA

•grading and staging of nephroblastoma

•nephron sparing techniques should be used for benign tumors and bilateral disease to reduce the risk of renal failure

SURGICAL ONCOLOGY

SOCIETY

RESEARCH

EDUCATION

LINKS

EMPLOYMENT

 IMAGE LIBRARYImages.html
● HistoryHistory.html
● What is a Surgical OncologistSurgical_Oncology_1.html
● Find a Surgical OncologistSurgical_Oncology_2.html
● Aims and ObjectivesAims.html
● MembershipMembership.html
● CommitteesCommittees.html
● NewsletterNewsletter.html
● Constitution and BylawsConstitution.html
● Research TrialsResearch_Trials.html
● Publications by MembersPublications.html
● Research OpportunitiesResearch_Opportunities.html
● Cancer InformationCancer_Information_1.html
● Conferences and MeetingsConferences.html
● Radiation FacilitiesRadiation_Facilities.html
● CE OpportunitiesCE_Opportunities.html
● Cancer InformationCancer_Information_2.html
● Current OpportunitiesEmployment_Opportunities.html
● Fellowship Training GuidelinesFellowship_Guidelines.html

RENAL CYSTADENOCARCINOMA

● Surgical Oncology JournalsJournals.html
● Surgical Oncology SocietiesSocieties.html
● Veterinary Surgery CollegesColleges.html

T0

No evidence of neoplasia

T1

Small tumor without deformation of the kidney

Primary Tumor

T2

Single tumor with deformation ± enlargement of the kidney

T3

Tumor invading perinephric structures ± pelvis or ureter ± renal blood vessels

N0

No evidence of regional lymph node involvement

N1

Ipsilateral regional lymph node involvement

Node

M0

No evidence of metastasis

M1

Evidence of distant metastasis with site specified with (a) single metastasis, (b) multiple metastasis in 1 organ, and (c) multiple metastasis in ≥ 2 organs

Metastasis

T4

Tumor invading adjacent organs

N2

Bilateral regional lymph node involvement

N3

Distant lymph node involvement